Vascular endothelial growth factor-delivery systems for cardiac repair: An overview

Theranostics

Volumn 2, Issue 6, 2012, Pages 541-552

  Simón Yarza, Teresa ^a   Formiga, Fabio R ^a   Tamayo, Esther ^a   Pelacho, Beatriz ^b   Prosper, Felipe ^b   Blanco Prieto, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Angiogenesis; Cardiovascular disease; Protein delivery; Tissue engineering; Vegf

Indexed keywords

ASPARAGINASE MACROGOL; BEVACIZUMAB; GOSERELIN; HUMAN GROWTH HORMONE; NANOPARTICLE; OCTREOTIDE; PEGADEMASE; PEGINTERFERON ALPHA2A; PLACEBO; RECOMBINANT VASCULOTROPIN; SORAFENIB; SUNITINIB; VASCULOTROPIN;

ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; HEART MUSCLE ISCHEMIA; HEART SURGERY; HUMAN; LOW DRUG DOSE; MEMBRANE MICROPARTICLE; NONHUMAN; PROSTATE CANCER; REVIEW; TISSUE ENGINEERING;

EID: 84864413702     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.3682     Document Type: Review

References (77)

1. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel hepa-rin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989; 161: 851-8.
2. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989; 246: 1306-9.
3. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246: 1309-12.
4. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accu-mulation of ascites fluid. Science. 1983; 219: 983-5.
5. Patil AS, Sable RB, Kothari RM. Occurrence, biochemical profile of vascular endothelial growth factor (VEGF) isoforms and their functions in endochondral ossification. J Cell Physiol. 2012; 227: 1298-1308.
6. Vempati P, Popel AS, Mac Gabhann F. Formation of VEGF iso-form-specific spatial distributions governing angiogenesis: computa-tional analysis. BMC Syst Biol. 2011; 5: 59.
7. Grunewald FS, Prota AE, Giese A, Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in an-giogenic signaling. Biochim Biophys Acta. 2009; 1804: 567-80.
8. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-6.
9. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362: 841-4.
10. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and develop-ment of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391-400.
11. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol. 2006; 18: 615-21.
12. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and Drug Administration drug approval summary: Sunitinib mal-ate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007; 12: 107-13.
13. Smart N, Dube KN, Riley PR. Coronary vessel development and insight towards neovascular therapy. Int J Exp Pathol. 2009; 90: 262-83.
14. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473: 298-307.
15. Riley PR, Smart N. Vascularizing the heart. Cardiovasc Res. 2011; 91: 260-8.
16. Gibson C, Laham R, Giordano F. Magnitude and location of new angio-graphically apparent coronary collaterals following intravenous VEGF administration. J Am Coll Cardio. 1999; 1999: 65A.
17. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation. 2000; 101: 118-21.
18. Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, et al. A target-mediated model to describe the pharmacokinetics and hemody-namic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther. 2002; 72: 20-32.
19. Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ, Simons M, et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am Heart J. 2001; 142: 872-80.
20. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003; 107: 1359-65.
21. Sato K, Wu T, Laham RJ, Johnson RB, Douglas P, Li J, et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myo-cardial ischemia. J Am Coll Cardiol. 2001; 37: 616-23.
22. Cleland JL, Duenas ET, Park A, Daugherty A, Kahn J, Kowalski J, et al. Development of poly-(D,L-lactide--coglycolide) microsphere formula-tions containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release. 2001; 72: 13-24.
23. Grdisa M. The delivery of biologically active (therapeutic) peptides and proteins into cells. Curr Med Chem. 2011; 18: 1373-9.
24. Roncalli J, Tongers J, Losordo DW. Update on gene therapy for myocar-dial ischaemia and left ventricular systolic dysfunction or heart failure. Arch Cardiovasc Dis. 2010; 103: 469-76.
25. Njeim MT, Hajjar RJ. Gene therapy for heart failure. Arch Cardiovasc Dis. 2010; 103: 477-85.
26. Zachary I, Morgan RD. Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart. 2011; 97: 181-9.
27. Hinkel R, Trenkwalder T, Kupatt C. Gene therapy for ischemic heart disease. Expert Opin Biol Ther. 2011; 11: 723-37.
28. Jawad H, Lyon AR, Harding SE, Ali NN, Boccaccini AR. Myocardial tissue engineering. Br Med Bull. 2008; 87: 31-47.
29. Bhatia SK. Tissue engineering for clinical applications. Biotechnol J. 2010; 5: 1309-23.
30. Chew SY, Low WC. Scaffold-based approach to direct stem cell neural and cardiovascular differentiation: an analysis of physical and bio-chemical effects. J Biomed Mater Res A. 2011; 97: 355-74.
31. Chiu LL, Radisic M. Scaffolds with covalently immobilized VEGF and Angiopoietin-1 for vascularization of engineered tissues. Biomaterials. 2010; 31: 226-41.
32. Miyagi Y, Chiu LL, Cimini M, Weisel RD, Radisic M, Li RK. Biode-gradable collagen patch with covalently immobilized VEGF for myo-cardial repair. Biomaterials. 2011; 32: 1280-90.
33. Zhang P, Wu H, Wu H, Lu Z, Deng C, Hong Z, et al. RGD-conjugated copolymer incorporated into composite of poly(lactide-co-glycotide) and poly(L-lactide)-grafted nanohydroxyapatite for bone tissue engineering. Biomacromolecules. 2011; 12: 2667-80.
34. Toyokawa N, Fujioka H, Kokubu T, Nagura I, Inui A, Sakata R, et al. Electrospun synthetic polymer scaffold for cartilage repair without cul-tured cells in an animal model. Arthroscopy. 2010; 26: 375-83.
35. Xue C, Hu N, Gu Y, Yang Y, Liu Y, Liu J, et al. Joint Use of a Chi-tosan/PLGA Scaffold and MSCs to Bridge an Extra Large Gap in Dog Sciatic Nerve. Neurorehabil Neural Repair. 2012 Jan;26(1):96-106.
36. Lu JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA-based nano-technology. Expert Rev Mol Diagn. 2009; 9: 325-41.
37. Singh S, Wu BM, Dunn JC. The enhancement of VEGF-mediated angio-genesis by polycaprolactone scaffolds with surface cross-linked heparin. Biomaterials. 2011; 32: 2059-69.
38. Losi P, Briganti E, Magera A, Spiller D, Ristori C, Battolla B, et al. Tissue response to poly(ether)urethane-polydimethylsiloxane-fibrin composite scaffolds for controlled delivery of pro-angiogenic growth factors. Bio-materials. 2010; 31: 5336-44.
39. Ayres CE, Jha BS, Sell SA, Bowlin GL, Simpson DG. Nanotechnology in the design of soft tissue scaffolds: innovations in structure and function. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 2: 20-34.
40. Gaikwad V, Patil A, Gaikwad M. Scaffolds for Drug Delivery in Tissue Engineering. International Journal of Pharmaceutical Sciences and Nan-otechnology. 2008; 1: 113-22.
41. Wu J, Zeng F, Huang XP, Chung JC, Konecny F, Weisel RD, et al. Infarct stabilization and cardiac repair with a VEGF-conjugated, injectable hy-drogel. Biomaterials. 2011; 32: 579-86.
42. Wu KH, Han ZC, Mo XM, Zhou B. Cell delivery in cardiac regenerative therapy. Ageing Res Rev. 2012 Jan;11(1):32-40.
43. Tengood JE, Kovach KM, Vescovi PE, Russell AJ, Little SR. Sequential delivery of vascular endothelial growth factor and sphingosine 1-phosphate for angiogenesis. Biomaterials. 2010; 31: 7805-12.
44. Porter AM, Klinge CM, Gobin AS. Biomimetic hydrogels with VEGF induce angiogenic processes in both hUVEC and hMEC. Biomacromol-ecules. 2011; 12: 242-6.
45. Zieris A, Prokoph S, Levental KR, Welzel PB, Grimmer M, Freudenberg U, et al. FGF-2 and VEGF functionalization of starPEG-heparin hydro-gels to modulate biomolecular and physical cues of angiogenesis. Bio-materials. 2010; 31: 7985-94.
46. Zieris A, Chwalek K, Prokoph S, Levental KR, Welzel PB, Freudenberg U, et al. Dual independent delivery of pro-angiogenic growth factors from starPEG-heparin hydrogels. J Control Release. 2011;156(1):28-36.
47. Silva EA, Mooney DJ. Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials. 2010; 31: 1235-41.
48. Jia X, Zhao C, Li P, Zhang H, Huang Y, Li H, et al. Sustained Release of VEGF by Coaxial Electrospun Dextran/PLGA Fibrous Membranes in Vascular Tissue Engineering. J Biomater Sci Polym Ed. 2010; 22: 1811-27.
49. Chapanian R, Amsden BG. Combined and sequential delivery of bioac-tive VEGF165 and HGF from poly(trimethylene carbonate) based pho-to-cross-linked elastomers. J Control Release. 2010; 143: 53-63.
50. Parajo Y, D'Angelo I, Welle A, Garcia-Fuentes M, Alonso MJ. Hyaluronic acid/Chitosan nanoparticles as delivery vehicles for VEGF and PDGF-BB. Drug Deliv. 2010; 17: 596-604.
51. Chung YI, Kim SK, Lee YK, Park SJ, Cho KO, Yuk SH, et al. Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex. J Control Release. 2010; 143: 282-9.
52. Golub JS, Kim YT, Duvall CL, Bellamkonda RV, Gupta D, Lin AS, et al. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am J Physiol Heart Circ Physiol. 2010; 298: H1959-65.
53. Karal-Yilmaz O, Serhatli M, Baysal K, Baysal BM. Preparation and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(D,L-lactic-co-glycolic acid) microspheres using a double emulsion/solvent evaporation technique. J Microencapsul. 2011; 28: 46-54.
54. Formiga FR, Pelacho B, Garbayo E, Abizanda G, Gavira JJ, Simon-Yarza T, et al. Sustained release of VEGF through PLGA microparticles im-proves vasculogenesis and tissue remodeling in an acute myocardial is-chemia-reperfusion model. J Control Release. 2010; 147: 30-7.
55. Nagai N, Kumasaka N, Kawashima T, Kaji H, Nishizawa M, Abe T. Preparation and characterization of collagen microspheres for sustained release of VEGF. J Mater Sci Mater Med. 2010; 21: 1891-8.
56. Daugherty AL, Rangell LK, Eckert R, Zavala-Solorio J, Peale F, Mrsny RJ. Sustained release formulations of rhVEGF produce a durable response in a murine model of peripheral angiogenesis. Eur J Pharm Biopharm. 2011; 78: 289-97.
57. Des Rieux A, Ucakar B, Mupendwa BP, Colau D, Feron O, Carmeliet P, et al. 3D systems delivering VEGF to promote angiogenesis for tissue en-gineering. J Control Release. 2011; 150: 272-8.
58. Jay SM, Shepherd BR, Andrejecsk JW, Kyriakides TR, Pober JS, Saltzman WM. Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization. Biomaterials. 2010; 31: 3054-62.
59. Amsden BG, Timbart L, Marecak D, Chapanian R, Tse MY, Pang SC. VEGF-induced angiogenesis following localized delivery via injectable, low viscosity poly(trimethylene carbonate). J Control Release. 2010; 145: 109-15.
60. Gao J, Liu J, Gao Y, Wang C, Zhao Y, Chen B, et al. A Myocardial Patch Made of Collagen Membranes Loaded with Collagen-Binding Human Vascular Endothelial Growth Factor Accelerates Healing of the Injured Rabbit Heart. Tissue Eng Part A. 2011 Nov;17:2739-47.
61. Padera R, Venkataraman G, Berry D, Godavarti R, Sasisekharan R. FGF-2/fibroblast growth factor receptor/heparin-like glycosaminogly-can interactions: a compensation model for FGF-2 signaling. Faseb J. 1999; 13: 1677-87.
62. Springer BA, Pantoliano MW, Barbera FA, Gunyuzlu PL, Thompson LD, Herblin WF, et al. Identification and concerted function of two receptor binding surfaces on basic fibroblast growth factor required for mitogen-esis. J Biol Chem. 1994; 269: 26879-84.
63. Wissink MJ, Beernink R, Poot AA, Engbers GH, Beugeling T, van Aken WG, et al. Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J Control Release. 2000; 64: 103-14.
64. Chen FM, Zhang M, Wu ZF. Toward delivery of multiple growth factors in tissue engineering. Biomaterials. 2010; 31: 6279-308.
65. Tamilvanan S, Venkatesh Babu R, Kannan K, Basu SK, Sa B. Manufac-turing techniques and excipients used during the design of biodegrada-ble polymer-based microspheres containing therapeutic peptide/protein for parenteral controlled drug delivery. PDA J Pharm Sci Technol. 2008; 62: 125-54.
66. Sollohub K, Cal K. Spray drying technique: II. Current applications in pharmaceutical technology. J Pharm Sci. 2010; 99: 587-97.
67. Vasita R, Katti D. Microparticle-Based Growth Factor Delivery Systems in Tissue Engineering. In: Ravi KM, editor. Handbook of particulated drug delivery. Stevenson Ranch: American Scientific Publishers. 2008: 291-310.
68. del Barrio GG, Novo FJ, Irache JM. Loading of plasmid DNA into PLGA microparticles using TROMS (Total Recirculation One-Machine System): evaluation of its integrity and controlled release properties. J Control Release. 2003; 86: 123-30.
69. Garbayo E, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ. Sustained release of bioactive glycosylated glial cell-line derived neu-rotrophic factor from biodegradable polymeric microspheres. Eur J Pharm Biopharm. 2008; 69: 844-51.
70. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008; 132: 171-83.
71. Houchin ML, Topp EM. Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms. J Pharm Sci. 2008; 97: 2395-404.
72. Schwendeman SP. Recent advances in the stabilization of proteins en-capsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst. 2002; 19: 73-98.
73. Beohar N, Rapp J, Pandya S, Losordo DW. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am Coll Cardiol. 2010; 56: 1287-97.
74. Hao X, Silva EA, Mansson-Broberg A, Grinnemo KH, Siddiqui AJ, Dellgren G, et al. Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Car-diovasc Res. 2007; 75: 178-85.
75. van Ramshorst J, Rodrigo SF, Schalij MJ, Beeres SL, Bax JJ, Atsma DE. Bone marrow cell injection for chronic myocardial ischemia: the past and the future. J Cardiovasc Transl Res. 2011; 4: 182-91.
76. Dib N, Khawaja H, Varner S, McCarthy M, Campbell A. Cell therapy for cardiovascular disease: a comparison of methods of delivery. J Cardiovasc Transl Res. 2011; 4: 177-81.
77. Cristallini C, Gagliardi M, Barbani N, Giannessi D, Guerra GD. Novel biodegradable, biomimetic and functionalised polymer scaffolds to prevent expansion of post-infarct left ventricular remodelling. J Mater Sci Mater Med. 2012 Jan;23(1):205-16.